Model Medicines
Model Medicines is a pharmatech company dedicated to transforming the drug discovery and development industry by leveraging artificial intelligence (AI) and machine learning (ML). Founded in 2019 and based in La Jolla, CA, the company focuses on accelerating the creation of life-changing drugs, with a pipeline of over 90 assets targeting oncology, infectious diseases, gastric, neurological, and weight disorders. Their mission is to develop best-in-class therapeutics efficiently, emphasizing innovation at the intersection of data science, biology, and drug development.
Industries
Nr. of Employees
small (1-50)
Model Medicines
5120 Shoreham Place, Suite 285, La Jolla, CA 92122
Patents
Products
Preclinical small-molecule candidate portfolio
A portfolio of AI-discovered small-molecule candidates across multiple therapeutic areas with reported discovery metrics and in vitro/in vivo validation results.
Preclinical small-molecule candidate portfolio
A portfolio of AI-discovered small-molecule candidates across multiple therapeutic areas with reported discovery metrics and in vitro/in vivo validation results.
Services
Collaborative discovery engagements that combine generative AI and molecular-embedding models with targeted in vitro cellular assays to generate and validate novel small-molecule candidates against specific targets.
Project-based partnerships to advance validated hits through medicinal-chemistry optimization and candidate nomination, including arrangements for independent preclinical validation with external laboratories.
Collaborative discovery engagements that combine generative AI and molecular-embedding models with targeted in vitro cellular assays to generate and validate novel small-molecule candidates against specific targets.
Project-based partnerships to advance validated hits through medicinal-chemistry optimization and candidate nomination, including arrangements for independent preclinical validation with external laboratories.
Expertise Areas
- AI-driven small-molecule discovery
- Generative molecular design and large-scale chemical-space exploration
- Graph neural network models for molecular prediction
- Preclinical development and in vivo efficacy demonstration
Key Technologies
- Generative models for small-molecule design
- Geometric/graph neural networks
- Molecular embedding vectors
- Deep learning for toxicity and mutagenicity prediction
News & Updates
Join Model Medicines in San Diego, California, on May 8-9 for the 20th BioPharma Drug Discovery Nexus Conference. Daniel Haders, CEO, will participate as a panelist, discussing advancing hit discovery for complex and emerging targets.
Announcement of selection for BARDA VANGUARD program, highlighting their focus on health security and public health threats.
Recognition as one of the top 15 innovative biotech companies to watch.
Development of AmesNet, a deep learning model with unprecedented sensitivity for mutagenicity prediction.
Highlighting their role in transforming drug discovery with AI.
Presented data on four drug programs including infectious disease, oncology, gastrointestinal motility, and inflammation.
Join Model Medicines in San Diego, California, on May 8-9 for the 20th BioPharma Drug Discovery Nexus Conference. Daniel Haders, CEO, will participate as a panelist, discussing advancing hit discovery for complex and emerging targets.
Announcement of selection for BARDA VANGUARD program, highlighting their focus on health security and public health threats.
Recognition as one of the top 15 innovative biotech companies to watch.
Development of AmesNet, a deep learning model with unprecedented sensitivity for mutagenicity prediction.
Highlighting their role in transforming drug discovery with AI.
Presented data on four drug programs including infectious disease, oncology, gastrointestinal motility, and inflammation.